XML 43 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
4. Segment Information and Concentrations
3 Months Ended
Sep. 30, 2012
Segment Reporting [Abstract]  
Segment Information and Concentrations

The Company views its operations as three segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors (ABenchtop Laboratory Equipment@), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis (A Catalyst Research Instruments@) and the marketing and production of bioprocessing systems for laboratory research in the biotechnology industry sold directly to customers and through distributors (“Bioprocessing Systems”).

 

Segment information is reported as follows:

 

    Benchtop Laboratory Equipment     Catalyst Research Instruments     Bioprocessing Systems     Corporate and Other     Consolidated  
Three months ended September 30, 2012:                              
                               
Net Sales   $ 1,064,900     $ 284,200     $ 2,600     $ 0     $ 1,351,700  
Foreign Sales     621,700       239,200       0       0       860,900  
Profit (Loss)     117,600       (134,300 )     (75,000 )     0       (91,700 )
Assets     2,556,900       987,000       801,000       1,521,200       5,866,100  
Long-Lived Asset Expenditures     2,100       17,400       0       0       19,500  
Depreciation and Amortization     11,100       9,300       23,900       0       44,300  

 

    Benchtop Laboratory Equipment     Catalyst Research Instruments     Bioprocessing Systems     Corporate and Other     Consolidated  
Three months ended September 30, 2011:                                        
                                         
Net Sales   $ 1,075,200     $ 465,800     $ 0     $ 0     $ 1,541,000  
Foreign Sales     608,700       112,600       0       0       721,300  
Profit (Loss)     135,800       (58,600 )     0       0       77,200  
Assets     2,621,100       1,078,300       0       1,333,400       5,032,800  
Long-Lived Asset Expenditures     8,200       46,700       0       0       54,900  
Depreciation and Amortization     11,800       35,300       0       0       47,100  

 

Approximately 61% and 63% of net sales of benchtop laboratory equipment for the three month periods ended September 30, 2012 and 2011, respectively, were derived from the Company’s main product, the Vortex-Genie 2® mixer, excluding accessories.

 

Two customers accounted in the aggregate for approximately 22% and 20% of the net salesof the Benchtop Laboratory Equipment Operations and 17% and 14% of the consolidated sales for the three months ended September 30, 2012, and 2011, respectively. Sales of catalyst research instruments generally comprise a few very large orders averaging at least $100,000 per order to a limited number of customers, who differ from order to order. Sales to five and three customers representedapproximately 97% and 91% of the Catalyst Research Instrument Operations’ net sales, respectively, and 17% and 28% of the consolidated sales for the three months ended September 30, 2012 and 2011, respectively.

 

The Company’s foreign sales are principally to customers in Europe and Asia.